Press Releases

Ashfield Engage, part of UDG Healthcare plc, announced that it has been selected by US-based Pacira BioSciences, Inc. to provide strategic commercialization services for its non-opioid pain management products in select European countries. Pacira has partnered with Ashfield Engage to...

Samsung Biologics, the world’s leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins. Under the terms of the agreement, Samsung Biologics will provide its end-to-end...

Increasing instances of substandard, falsified and counterfeit medical products continue to pose a major challenge to the global healthcare system which is already suffering from the dire impact of COVID-19. To address this issue, ASPA and Messe Frankfurt India...

Pfizer Inc and BioNTech SE  announced that the Conditional Marketing Authorization (CMA) for COMIRNATY® in the European Union (EU) has been expanded to include individuals 12 to 15 years of age. This follows the European Medicines Agency’s (EMA) Committee...

MedPharm Ltd, a world-leading contract developer of topical and transdermal pharmaceutical products, is opening a new location in Raleigh-Durham, North Carolina that will expand its CDMO services in topical and transdermal delivery. Doubling its existing footprint, the facility will support...

Aptamer Group Limited, the developer of Optimer™ Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, announce that they have entered into a strategic collaboration agreement. The agreement is to develop Optimer-drug conjugates for targeted drug delivery combining...

Moderna, Inc. , a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines,  announced that it has entered into an agreement with Thermo Fisher Scientific for fill/finish sterile manufacturing services and supply packaging for Moderna’s COVID-19 vaccine. Under the terms...